InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,584.54
(
-0.88%
)
US TECH 100
19,697.60
(
0.10%
)
Dow Jones
39,753.75
(
0.08%
)
Brent Oil
85.49
(
0.44%
)
Bitcoin
56,999.92
(
-0.61%
)
Post# of 252581
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120031
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biocqr post# 221228

Wednesday, 04/24/2019 11:32:52 AM

Wednesday, April 24, 2019 11:32:52 AM

Post# of 252581
ARWR earns $25M HBV milestone from JNJ for start of dosing a new phase-1/2 dosing cohort comprised of JNJ-3989 (f/k/a ARO-HBV) and two undisclosed drugs:

https://www.businesswire.com/news/home/20190424005179/en

The ct.gov listing for the trial provides no information on the identities of the undisclosed drugs (https://www.clinicaltrials.gov/ct2/show/NCT03365947 ).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up